After analysts at BofA and Cantor Fitzgerald singled out Alnylam Pharmaceuticals, the stock has surged over 2%.

Analysts have been focusing on Alnylam this week after it reported that its phase 3 trial evaluating acoramidis for the treatment of a rare heart disease failed to fulfill its primary endpoint, similar to BridgeBio.Blackstone and Alnylam Enter Into $2 Billion Strategic Financing  Collaboration to Accelerate the Advancement of RNAi Therapeutics | Business  Wire

Stifel announced shortly after that the news was good for Alnylam, which is now undertaking its phase 3 patisiran study. The company's stock, on the other hand, dropped by 17% on the day.

Alnylam's stock has started to recover some of its losses, but it is still down 11% in the last week.

Nonetheless, analyst Tazeen Ahmad maintains a buy rating and a $211 price target on the company, making it a top pick for next year at BofA. The analyst explained that Alnylam's stock has been volatile since the firm has the same primary endpoint as BridgeBio, but that Alnylam has "more stringent enrollment criteria is an advantage." which is an advantage.

Alnylam might be a top M&A target for 2022, according to Cantor Fitzgerald, with mergers and acquisitions being critical for industry values.